Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Ifetroban in Treating Patients with Malignant Solid Tumors at High Risk of Metastatic Recurrence

Multiple Cancer Types

This phase II trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment (recurrent) and spreading throughout the body (metastatic). Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.
Breast, Esophageal, Gastric/Gastroesophageal, Lung, Non Small Cell, Pancreatic, Small Cell
II
Mayer, Ingrid
NCT03694249
VICCMD1854

Pegylated Liposomal Doxorubicin Hydrochloride with Atezolizumab and / or Bevacizumab in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian

This phase II / III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and / or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent). Chemotherapy drugs, such as pegylated liposomal doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. It is not yet known which combination will work better in treating patients with ovarian, fallopian tube, or primary peritoneal cancer.
Ovarian
II/III
Brown, Alaina
NCT02839707
NRGGYN009

Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)

Head/Neck

This is a randomized, active-controlled, open-label study of pembrolizumab (Pembro) given prior to surgery and pembrolizumab in combination with standard of care radiotherapy (with or without cisplatin), as post-surgical therapy in treatment naïve participants with newly diagnosed Stage III / IVA, resectable, locoregionally advanced, head and neck squamous cell carcinoma (LA-HNSCC). Efficacy outcomes will be stratified by programmed cell death ligand 1 (PD-L1) combined positive score (CPS) status. The primary hypothesis is that pembrolizumab given before surgery and after surgery in combination with radiotherapy (with or without cisplatin) improves major pathological response and event-free survival compared to radiotherapy (with or without cisplatin) given after surgery alone.
Head/Neck
III
Gibson, Mike
NCT03765918
VICCHN1861

Nivolumab after Combined Modality Therapy in Treating Patients with High Risk Stage II-IIIB Anal Cancer

Gastrointestinal

This phase III trial investigates how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gastrointestinal
III
Ciombor, Kristen
NCT03233711
ECOGGIEA2165

A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer

Miscellaneous

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants with advanced solid tumors, including rearranged during transfection (RET)-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation.
Miscellaneous
I/II
Berlin, Jordan
NCT03157128
VICCPHI1873

Studying Health Outcomes after Treatment in Patients with Retinoblastoma, RIVERBOAT Study

Multiple Cancer Types

This trial studies health outcomes after treatment in patients with retinoblastoma. Gathering health information over time from patients and family members through vision assessments, samples of tissue and saliva, and questionnaires may help doctors learn more about what causes retinoblastoma, identify long-term health outcomes for patients with retinoblastoma, and find out which therapies may be the best for treating retinoblastoma.
Pediatrics, Retinoblastoma (Pediatrics)
N/A
Friedman, Debra
NCT03932786
VICCPED1878

US Cohort Study of Previously Untreated Patients (PUPs) with Congenital Hemophilia (PUPs Matter) (ATHN 8)

Hematologic

Hematologic
IV
Wheeler, Allison
VICCNCBH1884

Early Onset Pulmonary Events in Patients with Non-Small Lung Cancer or Other Cancers Taking Brigatinib or Other TKIs

Multiple Cancer Types

This phase II trial studies early onset pulmonary events in patients with non-small lung cancer and other cancers taking brigatinib or other TKIs. Severe side effects, including trouble breathing, coughing, pneumonia, and inflammation of the lungs (pneumonitis), have been seen in patients taking brigatinib. This study is being done to watch patients taking brigatinib and compare that experience with patients taking other drugs that also target ALK or ROS1 to study how often events like these occur. This study is also being done to observe patients who stopped brigatinib temporarily because of a suspected early onset pulmonary event, but then restarted brigatinib at the same dose to assess what experience they have.
Lung, Non Small Cell
II
Iams, Wade
NCT03389399
VICCTHO1885

Integrating Comprehensive Precision Tobacco Treatment for Patients with Cancer

Miscellaneous

Miscellaneous
N/A
Tindle, Hilary
VICCTHO1886

Gemcitabine Hydrochloride and Nivolumab with Carboplatin or Oxaliplatin in Treating Patients with Locally Advanced or Metastatic Urothelial Cancer

Urologic

This phase II trial studies how well gemcitabine hydrochloride and nivolumab with carboplatin or oxaliplatin work in treating patients with urothelial cancer that has spread from its original site of growth to nearby tissues or lymph nodes (locally advanced) or that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as gemcitabine hydrochloride, carboplatin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether gemcitabine hydrochloride and nivolumab with carboplatin or oxaliplatin may work better in treating patients with urothelial cancer.
Urologic
II
Davis, Nancy
NCT03451331
VICCURO1887

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: